Persistent itching (pruritus) is one of the most distressing symptoms experienced by patients with primary biliary cholangitis (PBC). In many individuals, the itching can become severe enough to disrupt sleep, impair quality of life, and lead to anxiety, depression, and social isolation. Conventional treatments often provide inadequate relief, leaving many patients with limited options.

In 2026, the FDA approved Lynavoy™ (linerixibat), the first oral ileal bile acid transporter (IBAT) inhibitor specifically indicated for the treatment of cholestatic pruritus associated with primary biliary cholangitis in adults. This novel therapy targets the enterohepatic circulation of bile acids and represents a major advancement in the management of PBC-related itching.

What Is Primary Biliary Cholangitis (PBC)?

Primary biliary cholangitis is a chronic autoimmune liver disease characterized by progressive destruction of the small intrahepatic bile ducts. As bile flow becomes impaired, bile acids accumulate within the liver and circulation, leading to symptoms such as:

• Persistent itching (pruritus)

• Fatigue

• Dry eyes and mouth

• Abdominal discomfort

• Progressive liver fibrosis and cirrhosis

Pruritus affects approximately 70–80% of patients with PBC and can occur at any stage of disease, even when liver function tests are relatively preserved.

Why Is PBC-Associated Pruritus Difficult to Treat?

The exact mechanism of cholestatic pruritus remains incompletely understood. However, elevated bile acids and other pruritogenic mediators are believed to contribute significantly.

Traditional therapies include:

• Cholestyramine

• Rifampicin

• Naltrexone

• Sertraline

Although these treatments may provide relief in some patients, many experience:

• Incomplete response

• Poor tolerability

• Drug interactions

• Treatment discontinuation

This unmet need has led to the development of targeted therapies such as linerixibat.

What Is Lynavoy (Linerixibat)?

Lynavoy (linerixibat) is an ileal bile acid transporter (IBAT) inhibitor approved by the U.S. FDA in 2026 for the treatment of cholestatic pruritus associated with primary biliary cholangitis in adults.

Unlike systemic medications, linerixibat works locally within the intestine and exhibits minimal systemic absorption.

Mechanism of Action

Linerixibat reversibly inhibits the ileal bile acid transporter (IBAT) located in the terminal ileum.

By blocking bile acid reabsorption:

• More bile acids are eliminated in stool.

• Circulating serum bile acid concentrations decrease.

• Pruritogenic mediators are reduced.

• Itching severity improves.

This targeted mechanism addresses one of the underlying pathways responsible for cholestatic pruritus.

Clinical Trial Evidence: The GLISTEN Study

The approval of Lynavoy was based on the GLISTEN trial (NCT04950127), a randomized, double-blind, placebo-controlled study involving 238 adults with PBC and moderate-to-severe pruritus.

Study Population

• Age range: 30–80 years

• 95% female

• 97% receiving ursodeoxycholic acid (UDCA)

• Treatment duration: 24 weeks

Improvement in Itch Severity

Patients rated their worst itch daily using an 11-point numeric rating scale.

Results at 24 Weeks

Importantly, improvements were seen as early as Week 2, demonstrating a relatively rapid onset of action.

Better Sleep Quality

Pruritus frequently interferes with sleep.

In the GLISTEN trial:

These findings suggest that reducing itch severity translates into clinically meaningful improvements in sleep and overall quality of life.

How Is Lynavoy Taken?

Recommended Dose

40 mg orally twice daily

Administration instructions:

• Take one tablet in the morning and one in the evening.

• Swallow whole.

• Take at least 30 minutes before food or beverages (except water).

Interaction with Bile Acid Resins

Patients taking:

• Cholestyramine

• Colesevelam

should administer Lynavoy:

• At least 4 hours before, or

• At least 4 hours after

these medications to avoid reduced efficacy.

Who Should Avoid Lynavoy?

Lynavoy should not be used in patients with:

• Decompensated cirrhosis

• Prior hepatic decompensation

• Ascites

• Hepatic encephalopathy

• Variceal hemorrhage

Safety in moderate or severe hepatic impairment has not been established.

Common Side Effects of Lynavoy

The most frequently reported adverse events include:

Diarrhea (62%)

The most common side effect.

Most cases:

• Occur within the first 20 days

• Are mild to moderate

• Resolve without discontinuation

Abdominal Pain (26%)

Usually mild.

Nausea (10%)

Elevated Liver Enzymes

• Increased ALT: 9%

• Increased AST: 8%

Monitoring of liver function tests is recommended.

Headache (8%)

Dyspepsia and Acid Reflux

Dizziness

Joint Pain (Arthralgia)

Fat-Soluble Vitamin Deficiency: An Important Consideration

Because linerixibat reduces bile acid reabsorption, absorption of vitamins A, D, E, and K may be impaired.

Healthcare providers should monitor:

• Vitamin A levels

• Vitamin D levels

• Vitamin E levels

• INR (reflecting vitamin K status)

Deficiencies should be corrected with supplementation.

Persistent deficiencies may necessitate discontinuation of therapy.

Bleeding Risk and Bone Health

Vitamin K deficiency may increase bleeding risk.

Patients should seek medical attention if they experience:

• Easy bruising

• Nosebleeds

• Gastrointestinal bleeding

• Prolonged bleeding

IBAT inhibitors have also been associated with bone fractures, emphasizing the importance of:

• Monitoring bone health

• Maintaining adequate vitamin D levels

• Correcting vitamin deficiencies promptly

Use During Pregnancy and Breastfeeding

Because systemic absorption of linerixibat is extremely low, fetal exposure is expected to be minimal.

However:

• Human pregnancy data are limited.

• Fat-soluble vitamin deficiency should be monitored carefully.

• Supplementation may be required.

Breastfeeding exposure is also expected to be low, although clinical data remain limited.

Advantages of Lynavoy

Targeted mechanism of action

Addresses bile acid-mediated pathways.

Minimal systemic absorption

Reduces risk of systemic toxicity.

Rapid improvement

Benefits observed within two weeks.

Improved sleep quality

Reduces nighttime symptoms.

Can be used with UDCA

No clinically significant impact on alkaline phosphatase response.

The Future of PBC Symptom Management

For decades, treatment of PBC-associated pruritus relied on off-label therapies with inconsistent efficacy and poor tolerability. The approval of Lynavoy (linerixibat) marks an important milestone in hepatology and offers a targeted option for patients suffering from debilitating cholestatic itching.

While monitoring for diarrhea, liver enzyme elevations, and fat-soluble vitamin deficiency remains essential, linerixibat provides a much-needed evidence-based therapy capable of improving both itching and sleep quality.

As research continues, IBAT inhibition may become a cornerstone in the management of cholestatic pruritus and significantly enhance quality of life for patients living with primary biliary cholangitis.

Key Takeaways

• Lynavoy (linerixibat) is FDA-approved for cholestatic pruritus associated with PBC.

• It works by inhibiting the ileal bile acid transporter (IBAT).

• Clinical trials demonstrated significant reductions in itch severity and sleep disturbance.

• Recommended dose is 40 mg twice daily, taken 30 minutes before meals.

• Diarrhea is the most common side effect.

• Monitoring liver tests and fat-soluble vitamins (A, D, E, K) is essential.

• Avoid use in patients with decompensated cirrhosis.

• Linerixibat represents one of the most important therapeutic advances in symptomatic management of PBC in recent years.

Keywords: Lynavoy, linerixibat, primary biliary cholangitis, PBC itching treatment, cholestatic pruritus, IBAT inhibitor, FDA approved PBC medication, bile acid transporter inhibitor, pruritus associated with PBC, liver disease itching treatment.